लोड हो रहा है...
Phase II Study Evaluating the Combination of Sorafenib and Temsirolimus in the Treatment of Radioactive Iodine-Refractory Thyroid Cancer
BACKGROUND: Patients with recurrent and/or metastatic radioactive iodine refractory thyroid carcinomas (RAI-TC) have limited treatment options. Sorafenib, an oral kinase inhibitor, is FDA approved for the treatment of RAI-TC but demonstrated low response rates (12.2%) as a single agent in the first...
में बचाया:
| में प्रकाशित: | Cancer |
|---|---|
| मुख्य लेखकों: | , , , , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
2017
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5650535/ https://ncbi.nlm.nih.gov/pubmed/28662274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30861 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|